|
Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer Clinical research trials and Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer. Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer clinical trial. Participants typically obtain the most effective healthcare available for their Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer  Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer
Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer
For Condition: Metastatic renal cell cancer
Status: Recruiting
Sponsor(s): Pfizer ,
Synopsis: The purpose of the study is to determine the activity of study drug in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy (interleukin-2 and/or interferon).
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: - Histologically documented renal cell cancer with metastases. (Patients with unresected primary tumors may be enrolled as long as evidence of metastatic disease is also present) - Failure of 1 prior cytokine based therapy (interleukin-2 and/or interferon) due to disease progression or unacceptable treatment related toxicity - At least one target lesion, as defined by RECIST, that has not been irradiated. (New lesions that have developed in a previously irradiated field may be used as sites of measurable disease assuming all other criteria are met) - Adequate bone marrow, hepatic, and renal function documented within 14 days prior to treatment - Age greater than or equal to 18 years - ECOG performance status of 0 or 1 - No evidence of preexisting uncontrolled hypertension - Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment - Written and voluntary informed consent
Total Enrollment: 52
Location and Contact Information:
Pfizer Investigational Site *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Madison, Wisconsin, 53792
United States
Recruiting
Pfizer Investigational Site *Recruiting*
New York City, New York, 10021
United States
Recruiting
Pfizer Investigational Site *Recruiting*
San Francisco, California, 94115
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Boston, Massachusetts, 02114
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Cleveland, Ohio, 44195
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting
Pfizer Investigational Site *Recruiting*
New York City, New York, 10021
United States
Recruiting
Additional Information:
Study ID Numbers: A4061012;
Study Start Date: November 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00076011
Other Metastatic Renal Cell Cancer Studies:
1. Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer
Related Studies:
Other Metastatic renal cell cancer Clinical Trials
Other Wisconsin Clinical Trials
Other Madison Clinical Trials
Phase 2 study of study drug as a second line treatment in patients with Metastatic Renal Cell Cancer
|
|
|
|
|
|
|
|
